Skip to main content
Erschienen in: Medical Oncology 5/2024

01.05.2024 | Original Paper

YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis

verfasst von: Yuanben Wang, Yulin Cao, Ying Chen, Han Cheng, Zhiang Liu, Mengna Wang, Yuyang Feng, Bojian Fei, Kaisa Cui, Zhaohui Huang

Erschienen in: Medical Oncology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) ranks as the third most prevalent cancer type globally. Nevertheless, the fundamental mechanisms driving CRC progression remain ambiguous, and the prognosis for the majority of patients diagnosed at an advanced stage is dismal. YWHA/14-3-3 proteins serve as central nodes in several signaling pathways and are closely related to tumorigenesis and progression. However, their exact roles in CRC are still poorly elucidated. In this study, we revealed that YWHAG was the most significantly upregulated member of the YWHA/14-3-3 family in CRC tissues and was associated with a poor prognosis. Subsequent phenotypic experiments showed that YWHAG promoted the proliferation, migration, and invasion of CRC cells. Mechanistically, RNA-seq data showed that multiple signaling pathways, including Wnt and epithelial-mesenchymal transition, were potentially regulated by YWHAG. CTTN was identified as a YWHAG-associated protein, and mediated its tumor-promoting functions by activating the Wnt/β-catenin signaling in CRC cells. In summary, our data indicate that YWHAG facilitates the proliferation, migration, and invasion of CRC cells by modulating the CTTN-Wnt/β-catenin signaling pathway, which offers a novel perspective for the treatment of CRC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA: Cancer J Clin. 2020;70(1):30. Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA: Cancer J Clin. 2020;70(1):30.
2.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49.PubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71(3):209–49.PubMed
3.
Zurück zum Zitat Mackintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J. 2004;381(Pt 2):329–42.PubMedPubMedCentralCrossRef Mackintosh C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J. 2004;381(Pt 2):329–42.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009;19(1):16–23.PubMedCrossRef Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009;19(1):16–23.PubMedCrossRef
5.
Zurück zum Zitat Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 2000;14(9):1027–47.PubMedCrossRef Pawson T, Nash P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 2000;14(9):1027–47.PubMedCrossRef
6.
Zurück zum Zitat Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889–97.PubMedCrossRef Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996;84(6):889–97.PubMedCrossRef
7.
Zurück zum Zitat Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell. 1997;91(7):961–71.PubMedCrossRef Yaffe MB, Rittinger K, Volinia S, Caron PR, Aitken A, Leffers H, et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell. 1997;91(7):961–71.PubMedCrossRef
8.
Zurück zum Zitat Aitken A, Baxter H, Dubois T, Clokie S, Mackie S, Mitchell K, et al. Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans. 2002;30(4):351–60.PubMedCrossRef Aitken A, Baxter H, Dubois T, Clokie S, Mackie S, Mitchell K, et al. Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans. 2002;30(4):351–60.PubMedCrossRef
9.
Zurück zum Zitat Fan X, Cui L, Zeng Y, Song W, Gaur U, Yang M. 14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease. Int J Mol Sci. 2019;20(14):3518.PubMedPubMedCentralCrossRef Fan X, Cui L, Zeng Y, Song W, Gaur U, Yang M. 14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease. Int J Mol Sci. 2019;20(14):3518.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Fan T, Li R, Todd NW, Qiu Q, Fang H-B, Wang H, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res. 2007;67(16):7901–6.PubMedCrossRef Fan T, Li R, Todd NW, Qiu Q, Fang H-B, Wang H, et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res. 2007;67(16):7901–6.PubMedCrossRef
11.
Zurück zum Zitat Maxwell SA, Cherry EM, Bayless KJ. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(5):849–64.PubMedCrossRef Maxwell SA, Cherry EM, Bayless KJ. Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(5):849–64.PubMedCrossRef
12.
Zurück zum Zitat Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem. 2009;284(33):22379–89.PubMedPubMedCentralCrossRef Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem. 2009;284(33):22379–89.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Teo Z, Sng MK, Chan JSK, Lim MMK, Li Y, Li L, et al. Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3γ expression. Oncogene. 2017;36(46):6408–19.PubMedPubMedCentralCrossRef Teo Z, Sng MK, Chan JSK, Lim MMK, Li Y, Li L, et al. Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3γ expression. Oncogene. 2017;36(46):6408–19.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Lee JXT, Tan WR, Low ZS, Lee JQ, Chua D, Yeo WDC, et al. YWHAG deficiency disrupts the EMT-associated network to induce oxidative cell death and prevent metastasis. Adv Sci (Weinh). 2023;10(31): e2301714.PubMedCrossRef Lee JXT, Tan WR, Low ZS, Lee JQ, Chua D, Yeo WDC, et al. YWHAG deficiency disrupts the EMT-associated network to induce oxidative cell death and prevent metastasis. Adv Sci (Weinh). 2023;10(31): e2301714.PubMedCrossRef
15.
Zurück zum Zitat Zhang J, Cui K, Huang L, Yang F, Sun S, Bian Z, et al. SLCO4A1–AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling. J Biomed Sci. 2022;29(1):4.PubMedPubMedCentralCrossRef Zhang J, Cui K, Huang L, Yang F, Sun S, Bian Z, et al. SLCO4A1–AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling. J Biomed Sci. 2022;29(1):4.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Moon SJ, Choi HJ, Kye YH, Jeong GY, Kim HY, Myung JK, et al. CTTN overexpression confers cancer stem cell-like properties and trastuzumab resistance via DKK-1/WNT signaling in HER2 positive breast cancer. Cancers (Basel). 2023;15(4):1168.PubMedCrossRef Moon SJ, Choi HJ, Kye YH, Jeong GY, Kim HY, Myung JK, et al. CTTN overexpression confers cancer stem cell-like properties and trastuzumab resistance via DKK-1/WNT signaling in HER2 positive breast cancer. Cancers (Basel). 2023;15(4):1168.PubMedCrossRef
18.
Zurück zum Zitat Sekiba K, Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, et al. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. J Hepatol. 2022;76(1):53–62.PubMedCrossRef Sekiba K, Otsuka M, Funato K, Miyakawa Y, Tanaka E, Seimiya T, et al. HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. J Hepatol. 2022;76(1):53–62.PubMedCrossRef
19.
Zurück zum Zitat Radhakrishnan VM, Martinez JD. 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS ONE. 2010;5(7):e11433.PubMedPubMedCentralCrossRef Radhakrishnan VM, Martinez JD. 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS ONE. 2010;5(7):e11433.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Ko B-S, Lai IR, Chang T-C, Liu T-A, Chen S-C, Wang J, et al. Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum Pathol. 2011;42(1):129–35.PubMedCrossRef Ko B-S, Lai IR, Chang T-C, Liu T-A, Chen S-C, Wang J, et al. Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum Pathol. 2011;42(1):129–35.PubMedCrossRef
21.
Zurück zum Zitat Lee Y-S, Lee JK, Bae Y, Lee B-S, Kim E, Cho C-H, et al. Suppression of 14-3-3γ-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cells. Sci Rep. 2016;6:26413.PubMedPubMedCentralCrossRef Lee Y-S, Lee JK, Bae Y, Lee B-S, Kim E, Cho C-H, et al. Suppression of 14-3-3γ-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cells. Sci Rep. 2016;6:26413.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Xu J, Wang J, He Z, Chen P, Jiang X, Chen Y, et al. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Cell Death Dis. 2021;12(7):648.PubMedPubMedCentralCrossRef Xu J, Wang J, He Z, Chen P, Jiang X, Chen Y, et al. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Cell Death Dis. 2021;12(7):648.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Wang P, Deng Y, Fu X. MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 2017;482(4):935–41.PubMedCrossRef Wang P, Deng Y, Fu X. MiR-509-5p suppresses the proliferation, migration, and invasion of non-small cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun. 2017;482(4):935–41.PubMedCrossRef
24.
Zurück zum Zitat Garan LAW, Xiao Y, Lin WC. 14-3-3tau drives estrogen receptor loss via ERalpha36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci USA. 2022;119(43):e2209211119.PubMedPubMedCentralCrossRef Garan LAW, Xiao Y, Lin WC. 14-3-3tau drives estrogen receptor loss via ERalpha36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci USA. 2022;119(43):e2209211119.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007;67(7):3185–91.PubMedCrossRef Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res. 2007;67(7):3185–91.PubMedCrossRef
26.
Zurück zum Zitat Ding J, Zhu YT, Yang L, Tang J, Wang YY, Chen Y, et al. 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. Carcinogenesis. 2018;39(3):493–502.PubMedCrossRef Ding J, Zhu YT, Yang L, Tang J, Wang YY, Chen Y, et al. 14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. Carcinogenesis. 2018;39(3):493–502.PubMedCrossRef
27.
Zurück zum Zitat Hiraoka E, Mimae T, Ito M, Kadoya T, Miyata Y, Ito A, et al. Breast cancer cell motility is promoted by 14-3-3gamma. Breast Cancer. 2019;26(5):581–93.PubMedCrossRef Hiraoka E, Mimae T, Ito M, Kadoya T, Miyata Y, Ito A, et al. Breast cancer cell motility is promoted by 14-3-3gamma. Breast Cancer. 2019;26(5):581–93.PubMedCrossRef
28.
Zurück zum Zitat Ren XL, Qiao YD, Li JY, Li XM, Zhang D, Zhang XJ, et al. Cortactin recruits FMNL2 to promote actin polymerization and endosome motility in invadopodia formation. Cancer Lett. 2018;419:245–56.PubMedCrossRef Ren XL, Qiao YD, Li JY, Li XM, Zhang D, Zhang XJ, et al. Cortactin recruits FMNL2 to promote actin polymerization and endosome motility in invadopodia formation. Cancer Lett. 2018;419:245–56.PubMedCrossRef
29.
Zurück zum Zitat Li W, Lei T, Song X, Deng C, Lu J, Zhang W, et al. CBLC inhibits the proliferation and metastasis of breast cancer cells via ubiquitination and degradation of CTTN. J Recept Signal Transduct Res. 2022;42(6):588–98.PubMedCrossRef Li W, Lei T, Song X, Deng C, Lu J, Zhang W, et al. CBLC inhibits the proliferation and metastasis of breast cancer cells via ubiquitination and degradation of CTTN. J Recept Signal Transduct Res. 2022;42(6):588–98.PubMedCrossRef
30.
Zurück zum Zitat Jing X, Wu H, Ji X, Wu H, Shi M, Zhao R. Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncol Rep. 2016;36(4):1946–52.PubMedCrossRef Jing X, Wu H, Ji X, Wu H, Shi M, Zhao R. Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer. Oncol Rep. 2016;36(4):1946–52.PubMedCrossRef
31.
Zurück zum Zitat Wu H, Cheng X, Ji X, He Y, Jing X, Wu H, et al. Cortactin contributes to the tumorigenicity of colorectal cancer by promoting cell proliferation. Oncol Rep. 2016;36(6):3497–503.PubMedCrossRef Wu H, Cheng X, Ji X, He Y, Jing X, Wu H, et al. Cortactin contributes to the tumorigenicity of colorectal cancer by promoting cell proliferation. Oncol Rep. 2016;36(6):3497–503.PubMedCrossRef
32.
Zurück zum Zitat Wei C-Y, Zhu M-X, Yang Y-W, Zhang P-F, Yang X, Peng R, et al. Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12(1):21.PubMedPubMedCentralCrossRef Wei C-Y, Zhu M-X, Yang Y-W, Zhang P-F, Yang X, Peng R, et al. Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12(1):21.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.PubMedPubMedCentralCrossRef Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu Z, et al. TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):232.PubMedPubMedCentralCrossRef Tang Q, Chen J, Di Z, Yuan W, Zhou Z, Liu Z, et al. TM4SF1 promotes EMT and cancer stemness via the Wnt/β-catenin/SOX2 pathway in colorectal cancer. J Exp Clin Cancer Res. 2020;39(1):232.PubMedPubMedCentralCrossRef
Metadaten
Titel
YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis
verfasst von
Yuanben Wang
Yulin Cao
Ying Chen
Han Cheng
Zhiang Liu
Mengna Wang
Yuyang Feng
Bojian Fei
Kaisa Cui
Zhaohui Huang
Publikationsdatum
01.05.2024
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 5/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02349-x

Weitere Artikel der Ausgabe 5/2024

Medical Oncology 5/2024 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.